This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Background: Pain is a common adverse effect of RT in patients with HNC, and extended release analgesic options are limited due to high rates of dysphagia. Wax microsphere bound oxycodone was developed ...

Dose reduction and discontinuation (N=894).

ASCO Global Leadership programs are under the purview of ASCO’s Regional Councils. Each yearlong program is designed to create a talented, regional network of clinicians who are empowered to identify ...

If you are interested in becoming a leader at ASCO, the Leadership Development Program (LDP) is for you. Participants learn valuable leadership skills, gain exposure to the roles and mission of ASCO, ...

Background: Systemic therapy with atezolizumab and bevacizumab (atezo/bev) has improved outcomes for advanced HCC, but results in objective responses in fewer than 30% of patients. Stereotactic body ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Survival rates in the overall group and the most commonly observed types of tumors.

Range in months (N = no. of studies) of median PFS and OS in clinical trials (CT) and observational studies (Obs) by LOT (any intervention) and by intervention (any LOT).

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...